<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296567</url>
  </required_header>
  <id_info>
    <org_study_id>ML29189</org_study_id>
    <nct_id>NCT02296567</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients</brief_title>
  <official_title>Comparison of Pharmacokinetics of and Effect on Systemic Vascular Endothelial Growth Factor (VEGF) Levels Over Time of Intravitreal Ranibizumab and Bevacizumab and Aflibercept in Age Related Macular Degeneration Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Florida Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>East Florida Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea (
      aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF)
      in the systemic circulation of Age Related Macular Degeneration patients currently treated
      with these medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine plasma levels of VEGF and serum Pharmacokinetic (PK) levels after varying
      lengths of time following intravitreal injection with Avastin, Lucentis, or Eylea in
      exudative macular degeneration. Patients will be tested while following a normal course of
      treatment in our institute. All screenings and testing will be conducted in three study
      visits.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum and plasma levels of free Vascular Endothelial Growth Factor</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Serum and plasma levels of free vascular endothelial growth factor will be measured up to 8 weeks following the standard of care treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum drug levels in nanomoles (nM) units following treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum levels of Ranibizumab, Bevacizumab, or Aflibercept will be measured up to 8 weeks following the standard of care treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of fluid (cubic mm) as measured by Ocular Coherence Tomography in the contralateral eye will be correlated with systemic Vascular Endothelial Growth Factor levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group 1 Lucentis 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Avastin 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Eylea 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Lucentis 6 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 Avastin 6 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 Eylea 6 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 Lucentis 8 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 Avastin 8 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9 Eylea 8 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10 Control Group no treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients who are not receiving anti-VEGF treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.</description>
    <arm_group_label>Group 1 Lucentis 4 weeks</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.</description>
    <arm_group_label>Group 2 Avastin 4 weeks</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.</description>
    <arm_group_label>Group 3 Eylea 4 weeks</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.</description>
    <arm_group_label>Group 4 Lucentis 6 weeks</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care</description>
    <arm_group_label>Group 5 Avastin 6 weeks</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care</description>
    <arm_group_label>Group 6 Eylea 6 weeks</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care</description>
    <arm_group_label>Group 7 Lucentis 8 weeks</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care</description>
    <arm_group_label>Group 8 Avastin 8 weeks</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care</description>
    <arm_group_label>Group 9 Eylea 8 weeks</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Control group Subjects will no previous anti-VEGF treatment</description>
    <arm_group_label>Group 10 Control Group no treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide written informed consent for participation in this study.

          2. Adults ≥ 50 years of age with exudative macular degeneration treated with Avastin,
             Lucentis, or Eylea in previously determined time intervals exclusive to a single
             anti-VEGF treatment type for not than three months.

          3. CONTROL GROUP: Age matched control group with no previously diagnosed exudative
             macular degeneration will also be enrolled.

          4. Provide signed informed consent.

        Exclusion Criteria:

          1. Uncontrolled blood pressure (defined as systolic &gt; 160mm Hg or Diastolic &gt; 95mm Hg
             while patient is sitting)

          2. Uncontrolled diabetes mellitus defined by Hemoglobin A1c (HbA1C &gt; 12% at screening)

          3. Concomitant ocular or systemic administration of drugs that may interfere with or
             potentiate the mechanism of action of anti-VEGF medications.

          4. Previous administration of systemic anti-angiogenic medications within 3 months

          5. Participation in a simultaneous medical investigation or trial.

          6. Treatment within 2 months with anti-VEGF agent in the fellow eye or anticipated need
             for further treatment during the study.

          7. Patients with any cancer diagnosis in remission for less than five years with the
             exception that patients with skin cancers, basal cell or squamous cell, treated
             exclusively or topical treatment will be allowed.

          8. Female patients who have not reached menopause, defined as cessation of menses for a
             minimum of twelve months with no perimenopausal symptoms.

          9. Patients who have significant wound healing during the trial.

         10. Patients with a history of vitrectomy in the study eye.

         11. patients with uncontrolled psoriasis, rheumatoid arthritis, osteoarthritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald E Frenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Florida Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronald E. Frenkel, MD</last_name>
    <phone>772.287.9000</phone>
    <email>info@efei.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>East Florida Eye Institute</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald E. Frenkel, MD</last_name>
      <phone>772-287-9000</phone>
      <email>info@efei.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Florida Eye Institute</investigator_affiliation>
    <investigator_full_name>Ronald E. Frenkel, MD</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

